Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding Ltd (OP: RHHVF )

271.38 UNCHANGED
Streaming Delayed Price Updated: 3:41 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Ltd

< Previous 1 2 3 4 5 6 Next >
Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder
The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder... 
Via Benzinga
FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19
The 
Via Benzinga
Exposures Product Safety
Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows
Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's... 
Via Benzinga
Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod
The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC: RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat... 
Via Benzinga
Exposures COVID-19 Product Safety
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway... 
Via Benzinga
Exposures Product Safety
Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy
Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic... 
Via Benzinga
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license... 
Via Benzinga
JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients
A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/... 
Via Benzinga
AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term follow-up data ... 
Via Benzinga
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting... 
Via Benzinga
Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer
Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti... 
Via Benzinga
Biogen, Bio-Thera's Biosimilar Referencing Tocilizumab Meets Primary Endpoints In Late-Stage Study
Biogen Inc (NASDAQ: BIIB) and China's Bio-Thera Solutions Ltd have announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing... 
Via Benzinga
AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid Leukemia
The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid... 
Via Benzinga
Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has entered into a multi-program research collaboration and license agreement with Genentech, a unit of ... 
Via Benzinga
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination... 
Via Benzinga
I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings
I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG’s (OTC: RHHBY)... 
Via Benzinga
Roche's Cobas COVID Test Scores EUA For Asymptomatic People
Roche Holdings AG’s (OTC: RHHBY) Cobas SARS-CoV-2 Test has received U.S. authorization for testing individuals without symptoms or reasons to suspect a COVID... 
Via Benzinga
Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing
Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early... 
Via Benzinga
India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail
Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for... 
Via Benzinga
Exposures COVID-19
Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer
The FDA’s Oncologic Drugs Advisory Committee voted 5-3 in favor of keeping Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) accelerated approval... 
Via Benzinga
Exposures Product Safety
Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has dosed the first patient in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in... 
Via Benzinga
Exposures COVID-19
FDA Oncology Adcomm Votes To Keep Conditional Approval For Roche's Tecentriq In Place For Now
The FDA kicked off a three-day meet to reexamine the accelerated approvals of immuno-oncology drugs with confirmatory trials that have not met their primary endpoint(s) and have... 
Via Benzinga
Exposures Product Safety
Roche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive Opinion
European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Roche Holdings AG’s (... 
Via Benzinga
Roche Backs 2021 Outlook Despite Lackluster Q1 Performance In Pharmaceuticals Division
Roche Holdings AG (OCTMKTS: RHHBY) posted Q1 sales of CHF 14.9 billion, up 3% Y/Y on a constant currency basis and down 1% on a reported basis. Sales in the... 
Via Benzinga
Cardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients
Cardiff Oncology Inc (NASDAQ: CRDF) has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.